SAA1 and arthritic joint disease: The result showed that both joint inflammation and synovial hyperplasia were reduced by administration of anti-SAA Ab (1 mg/kg), which supports the notion that SAA directly contributes to the development of arthritis (Figure 6E) and suggests that it could potentially be a therapeutic target.